Iovance Biotherapeutics, Inc. Q2 2026 Earnings Recap

Shares jumped 46.1% following a standout quarter driven by record Amtagvi revenue and an all-time high 56% margin, both materially exceeding guidance and market expectations.

Key Takeaways

• Q2 total revenue reached approximately $99 million, up 66% year-over-year and 39% sequentially.
• Amtagvi sales surged to about $91 million, exceeding the $79–81 million guidance range by a wide margin and growing 51% sequentially.
• Gross margin expanded sharply to 56%, up from 41% in Q1, reflecting improved operational efficiency and scale.
• Proleukin revenues were $9 million, down from $11 million in Q1 due to wholesaler inventory timing, but full-year contribution remains steady.
• Commercial momentum is supported by more than 50 patients treated monthly, broad pipeline progress, and a promising regulatory outlook including Fast Track designations.